NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

Georgetown University Medical Center (GUMC) seminar highlighted research on a revolutionary approach to cancer treatment: ...

Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...

The transaction, subject to regulatory approval, is expected to close later this year, a Cardinal spokesperson said.

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

ION’s more than 50 practice sites in 10 states will become members of Navista, Cardinal Health's oncology practice alliance ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Advances in treatment and new drugs are pushing cancer care even farther away from hospital campuses into outpatient settings ...

Vallina, from the CRIS Immuno-Oncology Unit, in Madrid (Spain), explains that a new approach provides 'trained troops' of ...

Kids facing cancer, along with their parents and medical teams, have a night of fun, music and dancing as the kids perform in ...

A new editorial was published in Oncotarget's Volume 15 on September 17, 2024, entitled, "The emerging role of AI in enhancing intratumoral immunotherapy care." ...